Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Lin, Tien Jen ^a,b,c,d   Lin, Hsin Ting ^a,b   Chang, Wei Ting ^b   Pradeep Mitapalli, S ^b,c,d   Hsiao, Pei Wen ^b,c,d   Yin, Shu Yi ^b   Yang, Ning Sun ^b,c,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d ACADEMIA SINICA   (Taiwan)

Author keywords

Anti metastasis; Dendritic cell vaccine; Immunogenic cells death; Shikonin

Indexed keywords

CALRETICULIN; DENDRITIC CELL VACCINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; SHIKONIN; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; CANCER VACCINE; NAPHTHOQUINONE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST METASTASIS; CANCER CELL DESTRUCTION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL LYSATE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; METASTASIS INHIBITION; MOUSE; NONHUMAN; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; HMGB1 PROTEIN; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; NAPHTHOQUINONES; PRECISION MEDICINE; T-LYMPHOCYTES;

EID: 84942324973     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0435-9     Document Type: Article

References (27)

1. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007;28(10):429-36. doi: 10.1016/j.it.2007.08.004.
2. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045. doi: 10.1146/annurev.iy.12.040194.005015.
3. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4(6):469-78. doi: 10.1038/nri1372.
4. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050-9. doi: 10.1038/nm1622.
5. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007;109(11):4839-45. doi: 10.1182/blood-2006-10-054221.
6. Tsan MF, Gao B. Heat shock proteins and immune system. J Leukoc Biol. 2009;85(6):905-10. doi: 10.1189/jlb.0109005.
7. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol. 2002;2(3):185-94. doi: 10.1038/nri749.
8. Chen HM, Wang PH, Chen SS, Wen CC, Chen YH, Yang WC, et al. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. Cancer Immunol Immunother. 2012;61(11):1989-2002. doi: 10.1007/s00262-012-1258-9.
9. Kim JB, Urban K, Cochran E, Lee S, Ang A, Rice B, et al. Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS One. 2010;5(2), e9364. doi: 10.1371/journal.pone.0009364.
10. Chang WT, Chen HM, Yin SY, Chen YH, Wen CC, Wei WC, et al. Specific Dioscorea Phytoextracts Enhance Potency of TCL-Loaded DC-Based Cancer Vaccines. Evid Based Complement Altern Med. 2013;2013:932040. doi: 10.1155/2013/932040.
11. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052-61. doi: 10.1158/0008-5472.CAN-09-3690.
12. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860-75. doi: 10.1038/nrc3380.
13. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta. 2010;1805(1):53-71. doi: 10.1016/j.bbcan.2009.08.003.
14. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54-61. doi: 10.1038/nm1523.
15. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-68. doi: 10.1038/nri3175.
16. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-74. doi: 10.1038/nri2506.
17. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791-802.
18. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140(6):798-804. doi: 10.1016/j.cell.2010.02.015.
19. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev. 2009;227(1):221-33. doi: 10.1111/j.1600-065X.2008.00731.x.
20. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47-59. doi: 10.1111/j.1600-065X.2007.00573.x.
21. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A. 2010;107(26):11942-7. doi: 10.1073/pnas.1003893107.
22. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011;11(7):802-7. doi: 10.1016/j.intimp.2011.01.003.
23. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63(15):4441-9.
24. Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, et al. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res. 2012;72(21):5483-93. doi: 10.1158/0008-5472.CAN-12-2236.
25. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72. doi: 10.1146/annurev-immunol-032712-100008.
26. Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death and Disease. 2013;4, e631. doi: 10.1038/cddis.2013.156.
27. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421(6925):852-6. doi: 10.1038/nature01441.